A scientific presentation on hemophilia by Bayer Biological Products (BP) was recognized as among the best at the recently held 48th annual meeting of the Society for Thrombosis and Hemostasis (GTH in Germany).

The presentation, entitled “Inter-domain disulfide bridge in rFVIII selectively blocks A2- dissociation-dependent loss of FVIIIa activity while preserving sensitivity to inactivation by APC,” received the Professor Landbeck award as the second-best abstract submitted to the meeting.

Klaus-Peter Radtke, senior staff scientist at RTP-based Bayer BP, presented the research at a special symposium honoring the top 10 abstracts. The research had been conducted collaboratively with Andrew Gale and John Griffin of The Scripps Research Institute in La Jolla, CA. The 10 selected research presentations were then judged by a panel which awarded Radtke and his collaborators the second place recognition.

“It is quite an honor for our research to be recognized by such a prestigious organization as GTH,” said Radtke. “Given the importance of this research to the global hemophilia community, this award is especially meaningful since it is part of a larger program to develop a recombinant factor VIII molecule that would require less frequent prophylactic dosing.”

The research focused on developing a recombinant factor VIII molecule that would have longer time of activity within the human body. As a result, people with hemophilia who infuse recombinant factor VIII prophylactically to prevent bleeding could do so less frequently.

“The focus of much of our research is to improve the quality of life of people living with hemophilia,” said Michael Mathews, vice president of global strategic marketing for the coagulation division of Bayer BP. “To better fulfill these needs, a treatment that requires less frequent infusions will not only be more convenient, but also will provide opportunities for individuals with hemophilia to live more easily the lives that they choose.”

Bayer BP: www.bayerbp.com